News

The findings of various studies point to alloimmunization being influenced by many different genetic and immunological factors.

IVIG is the current standard treatment for HDFN and FNAIT, but a new drug called nipocalimab has shown promise in an early clinical trial.

A clinical trial sponsored by Johnson & Johnson will seek to determine whether nipocalimab prevents or delays FNAIT in at-risk pregnancies.

A recently published case report describes a pregnancy complicated by systemic lupus erythematosus and FNAIT.

A recent study found that severe maternal thrombocytopenia may increase the risk of neonatal thrombocytopenia.

Some patients may experience severe reactions following HLA-1 alloimmunization from platelet transfusions.

A specialized form of MRI can help explain why cerebrospinal fluid builds up in newborns with brain bleeds, such as those seen in FNAIT.

The FREESIA-1 trial is testing a drug that could stop fetal and neonatal alloimmune thrombocytopenia before it starts.

A study by Rallybio is currently underway to determine whether the risk of FNAIT differs by race or ethnicity.

A recent study found non-nutritive pacifiers can be used to improve the pain response of infants undergoing venous blood collection.